HaniKushlafMDFAAN, FANA, FAANEM

Neuromuscular Medicine

Neuromuscular Neurologist, Professor, Neurology and Pathology, University of Cincinnati College of Medicine, Director of Neuromuscular Disorders Division , Director of Neuromuscular Research, Neuromuscular Medicine Fellowship Director, Director of UC Muscular Dystrophy Association (MDA) Care Center

Join to view full profile

Dr. Kushlaf is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Kushlaf's full profile

Already have an account?

Office
3113 Bellevue Ave
Cincinnati, OH 45219
Phone+1 513-475-8730

Fax+1 513-475-8033

Summary

Dr. Hani Kushlaf is a neuromuscular neurologist in Cincinnati, OH and is affiliated with multiple hospitals in the area, including the University of Cincinnati Medical Center, and Cincinnati Children's Hospital Medical Center. He received his medical degree from the University of Tripoli School of Medicine and has been in practice for more than 15 years. He also speaks multiple languages, including Arabic. He specializes in neuromuscular medicine and is experienced in muscular dystrophies, myasthenia gravis, Lambert-Eaton Myasthenic Syndrome (LEMS), Late-Onset Pompe Disease, myopathies, amyotrophic lateral sclerosis (ALS), peripheral neuropathies, chronic inflammatory demyelinating polyneuropathy (CIDP), and POEMS neuropathy.

Education & Training

University of CincinnatiPost-Baccalaureate Certificate Program in Clinical and Translational Research, Clinical and Translational Research, 2017 - 2018
Duke University HospitalFellowship, Neuromuscular Medicine (Neurology), 2011 - 2012
Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Neuromuscular Medicine (Neurology), 2010 - 2011
Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Neuromuscular Medicine (Neurology), 2009 - 2010
University of Kentucky College of MedicineChief Residency, Neurology, 2008 - 2009
University of Kentucky College of MedicineResidency, Neurology, 2005 - 2008
University of Tripoli School of MedicineClass of 2002

Certifications & Licensure

OH State Medical License 2012 - 2026
MN State Medical License 2009 - 2012
NC State Medical License 2011 - 2012
American Board of Psychiatry and Neurology Neurology
American Board of Psychiatry and Neurology Neuromuscular Medicine
American Board of Electrodiagnostic MedicineAmerican Board of Electrodiagnostic Medicine-Neuromuscular Ultrasound Certificate of Added Qualification
American Board of Electrodiagnostic MedicineElectrodiagnostic Medicine
The United Council of Neurologic SubspecialtiesClinical Neuromuscular Pathology

Awards, Honors, & Recognition

CastleConnolly Top Doctor CastleConnolly, 2017-2024
President’s Research Initiative Award AANEM, 2022
America's Most Honored Doctors American Registry, 2021
Alpha Omega Alpha Honor Medical Society Alpha Omega Alpha, 2020
America's Most Honored Doctors The American Registry, 2020
Cincy Best Docs CincyMagazine, 2020
On-Time Doctor Award Vitals, 2015, 2018, 2020
Patients’ Choice Award Vitals Patients Choice, 2008, 2018, 2020
Top Neurologist Ohio Magazine, 2019
Who's Who in America Marquis Who'sWho, 2019
America's Most Honored Professionals The American Registry, 2019
Compassionate Doctor Recognition Vitals, 2018
President’s Award AANEM, 2017
Junior Member Recognition Award American Association of Neuromuscular and Electrodiagnostic Medicine, 2012
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012
Join now to see all

Clinical Trials

Pharmacokinetics of Alglucosidase Alfa in Patients With Pompe Disease Start of enrollment: 2014 Nov 03
Completed
Phase 4
Safety and Efficacy Evaluation of Repeat neoGAA Dosing in Late Onset Pompe Disease Patients. Start of enrollment: 2013 Aug 19
Completed
Phase 1
BeatMG: Phase II Trial of Rituximab In Myasthenia Gravis Start of enrollment: 2014 May 01
Completed
Phase 2
Patient Assisted Intervention for Neuropathy: Comparison of Treatment in Real Life Situations Start of enrollment: 2014 Oct 01
Completed
Phase 4
A Study of HyQvia and Gammagard Liquid (Kiovig) in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Start of enrollment: 2015 Dec 15
Completed
Phase 3
Study to Compare the Efficacy and Safety of Enzyme Replacement Therapies Avalglucosidase Alfa and Alglucosidase Alfa Administered Every Other Week in Patients With Late-onset Pompe Disease Who Have Not Been Previously Treated for Pompe Disease Start of enrollment: 2016 Nov 02
Completed
Phase 3
Study to Evaluate Amifampridine Phosphate in Patients With MuSK-MG Start of enrollment: 2018 Apr 18
Completed
Phase 3
Long Term Safety Study of Amifampridine Phosphate in MuSK-MG (Muscle Specific Tyrosine Kinase Myasthenia Gravis) Start of enrollment: 2018 Jun 11
Terminated
Phase 3
A Study Comparing ATB200/AT2221 With Alglucosidase Alfa/Placebo in Adult Subjects With Late-onset Pompe Disease Start of enrollment: 2018 Dec 04
Completed
Phase 3
A Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of M281 Administered to Adults With Generalized Myasthenia Gravis Start of enrollment: 2019 Apr 10
Completed
Phase 2
An Extension Study of MOM-M281-004 to Evaluate the Safety, Tolerability, and Efficacy of M281 Administered to Patients With Generalized Myasthenia Gravis Start of enrollment: 2019 Aug 06
Terminated
Phase 2
Safety and Efficacy Study of Ravulizumab in Adults With Generalized Myasthenia Gravis Start of enrollment: 2019 Mar 12
Completed
Phase 3
A Study to Assess the Long-term Safety and Efficacy of ATB200/AT2221 in Adult Subjects With LOPD Start of enrollment: 2019 Dec 18
Active, not recruiting
Phase 3
A Study of TAK-079 in People With Generalized Myasthenia Gravis Start of enrollment: 2020 Jan 14
Completed
Phase 2
A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves) Start of enrollment: 2020 Sep 18
Active, not recruiting
Phase 2
A Study to Assess the Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves) Start of enrollment: 2020 Apr 15
Completed
Phase 2
Myasthenia Gravis Inebilizumab Trial Start of enrollment: 2020 Aug 30
Active, not recruiting
Phase 3
Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy (GRAND CANYON) Start of enrollment: 2022 Jul 06
Recruiting
Phase 2
Safety and Efficacy of Pitolisant on Excessive Daytime Sleepiness and Other Non-Muscular Symptoms in Patients With Myotonic Dystrophy Type 1 Start of enrollment: 2021 Jun 28
Active, not recruiting
Phase 2
A Study to Examine the Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Adult Patients With Symptomatic Generalized Myasthenia Gravis Start of enrollment: 2021 Dec 14
Recruiting
Phase 3
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

Advances in Disease-Modifying Therapeutics for Chronic Neuromuscular Disorders.
Long Davalos, Hani Kushlaf
Seminars in Respiratory and Critical Care Medicine. 2024-12-21
Telemedicine for the Care of Patients with Idiopathic Inflammatory Myopathies: Experience, Insights and Future Directions from the International Myositis Assessment an...
Jessica Day, Hani Kushlaf, Stacey Tarvin, Lorenzo Cavagna, Veronica Codullo
Current Rheumatology Reports. 2024-12-01
Switching treatment to cipaglucosidase alfa plus miglustat positively affects patient-reported outcome measures in patients with late-onset Pompe disease.
Priya S Kishnani, Barry J Byrne, Kristl G Claeys, Jordi Díaz-Manera, Mazen M Dimachkie
Journal of Patient-Reported Outcomes. 2024-11-13

Journal Articles

Ultrasound diagnosis of bony nerve entrapment: Case series and literature review.
Erra C, Granata G, Liotta G, Podnar S, Giannini M, Kushlaf H, Hobson-Webb LD, Leversedge FJ, Martinoli C, Padua L., Muscle Nerve

Press Mentions

Researchers Find a New Treatment for Rare Muscular DiseaseApril 16th, 2021
For Springfield Township man, hope comes from an ice bucketFebruary 12th, 2021
Most effective drugs for common type of neuropathic pain Clinical study tested four different types of medications for efficacy, tolerability and adverse effectsFebruary 12th, 2021
Join now to see all

Committees

Member, American Board of Electrodiagnostic Medicine Maintenance of Certification Program Examination Committee 2018 - Present
Member, American Association of Neuromuscular and Electrodiagnostic Medicine- Neuromsucular Self-Assessment Committee 2016 - 2020
Member, American Association of Neuromuscular and Electrodiagnostic Medicine Electrodiagnostic Self-Assessment Committee 2013 - 2016